Clinical trial · Observational
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient\'s clinical features. The analyses generated will contribute to the design and improvement of innovative therapeutic antibodies acting on the immune system
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Urologic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood collection | Procedure | — | UNRESOLVED |
| tissue specimen collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cohort 1 - Patients with solid tumor undergoing surgery
- description
- Cohort 1 (patients with solid tumor undergoing surgery): * Head and neck cancer: up to 80 patients * Urologic cancer: up to 160 patients * Liver cancer: up to 80 patients * Colorectal and gastric cancer: up to 80 patients * Breast cancer: up to 80 patients A maximum of 3 visits are planned : * Screening visit for patient evaluation and inclusion/exclusion criteria review * Visit 1: For blood sampling specifically for the study * Visit 2: For tumor sampling and blood sampling if not done at Visit 1 Fresh solid tumor lesions and normal adjacent tissue will be macroscopically selected from the resected tumor material by a pathologist. Samples will be collected according to decision of May 3, 2017 establishing a list of researches as mentioned by article L1121-1, paragraph 2° of the French public Health code, and will therefore only concern blood samples, as well tissues collected during surgeries. The Screening visit and the Visit 1 can occur on the same day.
- interventionNames
- Procedure: blood collection
- Procedure: tissue specimen collection
- label
- Cohort 2 - Patients with solid tumor with anti-PD1/PD-L1 treatment and no surgery
- description
- * Lung cancer: up to 40 patients * Head and neck cancer: up to 40 patients a maximum of 3 visits are planned during this period: * A Screening visit for patient evaluation and inclusion/exclusion criteria review. * A Baseline visit (pre-treatment) visit for blood sampling specifically for the study * A post-treatment visit (after immunotherapy administration) for blood sampling specifically for the study The Screening and Baseline visits can occur on the same day.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications * Written informed consent signed from subject prior to performing any protocol-related procedures Exclusion Criteria: * Use of any investigational agent within 14 days prior first visit; * Patient under guardianship/trusteeship or legally incapacitated person; * Patient unable to understand read and/or sign an informed consent; * Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties; * Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme; * Patients who are known to be HIV positive
References
Publications (0)
Data not yet available